Lipid Metabolism Practice Questions

Q: What is the end product of even-chain fatty acid oxidation?

Acetyl Co-A. **Explanation:** The oxidation of fatty acids primarily occurs via the **$\beta$-oxidation pathway** within the mitochondria. **1. Why Acetyl-CoA is correct:** In the $\beta$-oxidation of **even-chain fatty acids** (e.g., Palmitic acid), the fatty acid chain undergoes a repetitive four-step cycle (oxidation, hydration, oxidation, and thiolysis). In each cycle, two carbon atoms are cleaved from the carboxyl end of the fatty acyl-CoA molecule. The final cleavage of a four-carbon intermediate (Acetoacetyl-CoA) yields **two molecules of Acetyl-CoA**. Therefore, the entire even-chain fatty acid is completely degraded into Acetyl-CoA units, which then enter the TCA cycle for ATP production. **2. Why other options are incorrect:** * **Propionyl-CoA:** This is the end product of **odd-chain fatty acid** oxidation. In the final round of $\beta$-oxidation for odd-chain fats, a five-carbon fragment is cleaved into one Acetyl-CoA and one three-carbon Propionyl-CoA. * **Malonyl-CoA:** This is an intermediate of **fatty acid synthesis** (lipogenesis), not oxidation. It acts as a potent inhibitor of Carnitine Palmitoyltransferase-I (CPT-I), preventing a futile cycle by stopping fatty acid breakdown while synthesis is active. **Clinical Pearls for NEET-PG:** * **Site:** $\beta$-oxidation occurs in the mitochondrial matrix; Fatty acid synthesis occurs in the cytosol. * **Rate-limiting step:** The transport of fatty acids into the mitochondria via the **Carnitine Shuttle** (inhibited by Malonyl-CoA). * **Energy Yield:** Oxidation of one molecule of Palmitate (16C) yields a net of **106 ATP**. * **Odd-chain metabolism:** Propionyl-CoA is converted to Succinyl-CoA (a TCA cycle intermediate) via a Vitamin B12-dependent pathway. This makes odd-chain fatty acids **glucogenic**.

Q: Which of the following is not a ketone body?

Acetic acid. **Explanation:** Ketone bodies are water-soluble molecules produced by the liver from fatty acids during periods of low food intake (fasting), carbohydrate restrictive diets, or untreated type 1 diabetes. The process, known as **ketogenesis**, occurs in the mitochondrial matrix of hepatocytes. **Why Acetic Acid is the Correct Answer:** Acetic acid (Option B) is a two-carbon carboxylic acid. While it is related to the metabolism of Acetyl-CoA, it is **not** classified as a ketone body. In the context of metabolism, acetic acid is usually found in its activated form, Acetyl-CoA, which serves as the precursor for ketogenesis but is not a ketone body itself. **Analysis of Incorrect Options:** * **Acetoacetate (Option C):** This is the "primary" ketone body synthesized from Acetyl-CoA. It is a true keto-acid. * **Beta-hydroxybutyric acid (Option D):** Formed by the reduction of acetoacetate. Although technically a hydroxy-acid (lacking a keto group), it is clinically and biochemically classified as a ketone body. It is the most abundant ketone body in the blood during ketosis. * **Acetone (Option A):** Produced by the spontaneous non-enzymatic decarboxylation of acetoacetate. It is highly volatile and excreted via the lungs. **NEET-PG High-Yield Pearls:** 1. **Site of Synthesis:** Liver (mitochondria); however, the liver **cannot** utilize ketone bodies because it lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase). 2. **Rate-limiting Enzyme:** HMG-CoA Synthase (Mitochondrial). 3. **Detection:** The **Rothera’s Test** detects Acetoacetate and Acetone, but it does **not** detect Beta-hydroxybutyrate. 4. **Clinical Sign:** The "fruity odor" of the breath in Diabetic Ketoacidosis (DKA) is due to the excretion of Acetone.

Q: During fatty acid synthesis, humans cannot introduce double bonds beyond which position?

9. ### Explanation **1. Why Option C is Correct:** Human cells possess fatty acid desaturase enzymes (specifically $\Delta^4$, $\Delta^5$, $\Delta^6$, and $\Delta^9$ desaturases) that can introduce double bonds at specific locations in a fatty acid chain. However, humans **lack the enzymatic machinery** to introduce double bonds beyond the **$\Delta^9$ position** (counting from the carboxyl end). Specifically, we lack $\Delta^{12}$ and $\Delta^{15}$ desaturases, which are found in plants. Consequently, any fatty acid with a double bond beyond carbon 9 cannot be synthesized *de novo* and must be obtained through the diet. **2. Why Other Options are Incorrect:** * **Option A (4):** Humans do possess $\Delta^4$ desaturase, which is involved in the synthesis of highly unsaturated fatty acids like Docosahexaenoic acid (DHA). * **Option B (7):** While not a primary regulatory desaturase, the body can easily desaturate at positions before carbon 9. * **Option D (11):** This is beyond the human enzymatic capability. Double bonds at $\Delta^{12}$ or $\Delta^{15}$ are characteristic of essential fatty acids. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Essential Fatty Acids (EFAs):** Because we cannot desaturate beyond $\Delta^9$, **Linoleic acid (18:2; $\Delta^{9,12}$)** and **Linolenic acid (18:3; $\Delta^{9,12,15}$)** are nutritionally essential. * **Arachidonic Acid:** It is a $\omega$-6 fatty acid. It is considered "semi-essential" because it can be synthesized from Linoleic acid. * **Site of Synthesis:** Fatty acid desaturation occurs in the **Smooth Endoplasmic Reticulum (SER)**. * **Key Components:** The desaturase system requires **NADH, Cytochrome b5, and Mg²⁺**. * **Palmitoleic (16:1; $\Delta^9$) and Oleic acid (18:1; $\Delta^9$):** These are the most common monounsaturated fatty acids synthesized by the human $\Delta^9$ desaturase.

Q: A 45-year-old man on a fat-free, carbohydrate-rich diet for a certain time continues to gain weight and become obese. Which of the following lipoproteins is likely to be elevated in his blood?

VLDL. ### Explanation **Correct Option: B (VLDL)** The core concept here is **Endogenous Lipogenesis**. When a person consumes a diet high in carbohydrates but low in fat, the liver processes the excess glucose through glycolysis and the Citric Acid Cycle. The resulting excess Acetyl-CoA is diverted toward **De Novo Lipogenesis** (fatty acid synthesis). These newly synthesized triglycerides are packaged into **Very Low-Density Lipoproteins (VLDL)** in the liver and secreted into the bloodstream to be transported to adipose tissue for storage. Therefore, a high-carbohydrate diet directly stimulates hepatic VLDL production, leading to weight gain and elevated plasma VLDL levels. **Why Incorrect Options are Wrong:** * **A. Chylomicrons:** These transport **exogenous (dietary) lipids** from the intestine. Since the patient is on a fat-free diet, chylomicron production will be minimal. * **C. LDL:** While VLDL is eventually converted to LDL, the primary lipoprotein elevated due to immediate hepatic synthesis from carbohydrate excess is VLDL. LDL elevation is usually associated with cholesterol metabolism defects rather than acute carbohydrate loading. * **D. HDL:** Known as "good cholesterol," HDL is involved in reverse cholesterol transport. High carbohydrate intake often correlates with *decreased* HDL levels, not elevation. **NEET-PG High-Yield Pearls:** * **Rate-limiting enzyme for Fatty Acid Synthesis:** Acetyl-CoA Carboxylase (stimulated by Insulin). * **Apolipoprotein of VLDL:** Apo B-100 (Endogenous pathway). * **Apolipoprotein of Chylomicrons:** Apo B-48 (Exogenous pathway). * **Clinical Correlation:** High-carbohydrate diets are a common cause of **Hypertriglyceridemia** because VLDL is rich in triglycerides.

Q: High-density lipoprotein (HDL) levels are increased by which of the following?

Exercise. **Explanation:** **High-density lipoprotein (HDL)**, often referred to as "good cholesterol," plays a critical role in **Reverse Cholesterol Transport**, where it removes excess cholesterol from peripheral tissues and transports it back to the liver for excretion. **Why Exercise is Correct:** Physical activity, particularly aerobic exercise, is one of the most effective non-pharmacological ways to raise HDL levels. Exercise increases the activity of **Lipoprotein Lipase (LPL)** and decreases the activity of **Cholesteryl Ester Transfer Protein (CETP)**. This shift promotes the maturation of HDL particles and reduces their clearance, leading to a sustained increase in plasma HDL-C levels. **Analysis of Incorrect Options:** * **Vitamin E:** While Vitamin E is a potent lipid-soluble antioxidant that prevents the oxidation of LDL, clinical trials have not demonstrated a significant or consistent effect on increasing HDL levels. * **Aspirin:** Aspirin is an antiplatelet agent used for secondary prevention of cardiovascular events. It does not have a direct biochemical effect on lipoprotein synthesis or HDL concentration. * **DHEA (Dehydroepiandrosterone):** DHEA is an endogenous steroid. Clinical studies generally show that DHEA supplementation either has no effect or may actually **decrease** HDL levels, particularly in women. **Clinical Pearls for NEET-PG:** * **ApoA-I** is the primary apolipoprotein associated with HDL. * **LCAT (Lecithin-Cholesterol Acyltransferase)** is the enzyme responsible for converting nascent discoid HDL into mature spherical HDL. * **Factors that decrease HDL:** Smoking, obesity, sedentary lifestyle, and uncontrolled diabetes. * **Drug of choice to raise HDL:** Niacin (Vitamin B3) is the most potent pharmacological agent for increasing HDL, though its clinical use is limited by side effects like flushing.

Q: Deficiency of which enzyme causes Tay-Sachs disease?

Hexosaminidase A. **Explanation:** **Tay-Sachs Disease** is an autosomal recessive lysosomal storage disorder belonging to the group of **GM2 gangliosidoses**. It is caused by a deficiency of the enzyme **Hexosaminidase A**, which leads to the toxic accumulation of GM2 gangliosides, primarily within the neurons of the central nervous system. * **Why Option A is correct:** Hexosaminidase A (composed of $\alpha$ and $\beta$ subunits) requires an activator protein to degrade GM2 ganglioside. A mutation in the *HEXA* gene on chromosome 15 leads to enzyme deficiency, resulting in progressive neurodegeneration and the characteristic "cherry-red spot" on the macula [1]. * **Why incorrect options are wrong:** * **B. Alpha-L-iduronidase:** Deficiency causes **Hurler Syndrome** (Mucopolysaccharidosis I) [2], characterized by corneal clouding and hepatosplenomegaly. * **C. Alpha-galactosidase A:** Deficiency causes **Fabry Disease**, an X-linked disorder presenting with angiokeratomas, peripheral neuropathy, and renal failure. * **D. Acid alpha-glucosidase (Acid Maltase):** Deficiency causes **Pompe Disease** (Glycogen Storage Disease Type II), leading to massive cardiomegaly and muscular hypotonia. **High-Yield Clinical Pearls for NEET-PG:** 1. **Morphology:** Histology shows "onion-skin" appearance of lysosomes (whorled configurations) [1]. 2. **Clinical Triad:** Progressive neurodegeneration, developmental delay, and **Cherry-red spot** on the macula [1]. 3. **Key Distinction:** Unlike Gaucher or Niemann-Pick disease, Tay-Sachs has **NO hepatosplenomegaly**. 4. **Epidemiology:** High prevalence in the Ashkenazi Jewish population. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, p. 161. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 163-164.

Q: Which of the following is NOT a component of the multifunctional enzyme Fatty Acid Synthase Complex?

Monoamine oxidase. **Explanation:** The **Fatty Acid Synthase (FAS) complex** is a multi-enzyme system responsible for the de novo synthesis of palmitate from acetyl-CoA and malonyl-CoA. In humans, it exists as a **homodimer**, where each monomer contains seven distinct enzyme activities and an Acyl Carrier Protein (ACP) domain. **Why Monoamine Oxidase (MAO) is the correct answer:** Monoamine oxidase is an enzyme located on the **outer mitochondrial membrane** involved in the oxidative deamination of neurotransmitters (like epinephrine and serotonin). It has no role in lipid biosynthesis. Therefore, it is not a component of the FAS complex. **Analysis of incorrect options (Components of FAS):** * **Acetyl transacylase:** Transfers the acetyl group from Acetyl-CoA to the Cys-SH group of the enzyme to initiate synthesis. * **Malonyl transacylase:** Transfers the malonyl group from Malonyl-CoA to the -SH group of the ACP. * **Enoyl reductase:** Responsible for the second reduction step (using NADPH) to saturate the double bond, forming a saturated acyl-ACP. * *Other components include:* Ketoacyl synthase (condensing enzyme), Ketoacyl reductase, and Hydratase. **High-Yield NEET-PG Pearls:** 1. **Location:** Fatty acid synthesis occurs in the **cytosol**, whereas beta-oxidation occurs in the mitochondria. 2. **The "Primer":** Acetyl-CoA is the starting primer, but **Malonyl-CoA** is the immediate donor of 2-carbon units. 3. **Reducing Power:** **NADPH** is the essential coenzyme for FAS, primarily supplied by the Hexose Monophosphate (HMP) shunt. 4. **End Product:** The primary end product of the FAS complex is **Palmitate** (a 16-carbon saturated fatty acid). 5. **Structural Organization:** In eukaryotes, FAS is a **Type I system** (linked polypeptide chain), whereas in bacteria, it is a **Type II system** (individual separate enzymes).

Q: Which of the following organs cannot utilize fatty acids for energy metabolism, except?

Brain. ### Explanation The correct answer is **Brain**. **Why the Brain cannot utilize Fatty Acids:** The brain is highly dependent on glucose as its primary fuel source. It cannot utilize long-chain fatty acids for energy for two main reasons: 1. **Blood-Brain Barrier (BBB):** Fatty acids are transported in the blood bound to albumin. This large albumin-fatty acid complex cannot cross the BBB. 2. **Enzymatic Deficiency:** Even if small amounts of fatty acids enter the brain, the rate of **beta-oxidation** is extremely slow. High rates of beta-oxidation would increase oxygen demand and generate reactive oxygen species (ROS), potentially causing oxidative damage to neurons. *Note: During prolonged starvation, the brain adapts to use **ketone bodies**, but it never utilizes fatty acids directly.* **Analysis of Incorrect Options:** * **Liver (A):** The liver is the central hub for lipid metabolism. It actively performs beta-oxidation of fatty acids to generate ATP, especially during fasting. * **Muscle (B):** Resting skeletal muscle and cardiac muscle prefer fatty acids as their primary energy source. They have a high density of mitochondria to support beta-oxidation. * **Kidney (D):** The renal cortex utilizes fatty acids as its main fuel source to provide the energy required for active tubular reabsorption. **High-Yield NEET-PG Pearls:** * **RBCs** also cannot utilize fatty acids because they lack **mitochondria** (the site of beta-oxidation). * The brain's inability to use fatty acids is a protective mechanism to prevent **hypoxia** and **oxidative stress**. * In the fasting state, the liver converts fatty acids into **ketone bodies** (acetoacetate and β-hydroxybutyrate), which are the only lipid-derived molecules that can cross the BBB to provide energy.

Q: Saturated acyl enzyme formation causes:

Freeing of PAN-SH site. This question pertains to the **Fatty Acid Synthase (FAS) complex**, a multi-enzyme system responsible for de novo lipogenesis. ### Explanation of the Correct Answer The FAS complex is a dimer where each monomer contains two essential thiol (-SH) groups: the **Phosphopantetheine (PAN-SH)** site and the **Cysteine (Cyst-SH)** site. The process of fatty acid synthesis occurs in a repeating cycle of four steps: condensation, reduction, dehydration, and reduction. 1. Initially, the growing acyl chain is attached to the **PAN-SH** site. 2. During the **condensation step** (catalyzed by 3-ketoacyl synthase), the acyl group is transferred from the Cyst-SH site to the PAN-SH site to react with a malonyl group. 3. Once the four-step cycle is complete, a **saturated acyl enzyme** is formed, which is still attached to the **PAN-SH** site. 4. To begin the next round of elongation (adding the next 2-carbon unit), the saturated acyl group must be **transferred from the PAN-SH site to the Cyst-SH site**. This translocation **frees the PAN-SH site**, allowing it to receive a new malonyl-CoA molecule. ### Why Incorrect Options are Wrong * **B. Freeing of Cyst-SH site:** This is incorrect because the saturated acyl group moves *to* the Cysteine site, thereby occupying it, not freeing it. * **D. None:** Incorrect, as the translocation mechanism is a fundamental step in the FAS cycle to allow for chain elongation. ### High-Yield Clinical Pearls for NEET-PG * **Rate-limiting enzyme:** Acetyl-CoA Carboxylase (requires Biotin). * **End product:** Palmitate (16-carbon saturated fatty acid). * **Reducing equivalent:** NADPH is the essential co-factor (primarily from the HMP Shunt). * **Location:** Occurs in the **cytosol** (the "Citrate-Malate Shuttle" transports Acetyl-CoA from mitochondria to cytosol). * **Functional Unit:** The FAS complex is active only as a **dimer** arranged in a "head-to-tail" configuration.

Question 1

What is the end product of even-chain fatty acid oxidation?

Accepted Answer

Acetyl Co-A

Answer

Propionyl Co-A

Answer

Malonyl Co-A

Answer

None of the above

Question 2

Which of the following is not a ketone body?

Accepted Answer

Acetic acid

Answer

Acetone

Answer

Acetoacetate

Answer

Beta-hydroxybutyric acid

Question 3

During fatty acid synthesis, humans cannot introduce double bonds beyond which position?

Accepted Answer

9

Answer

4

Answer

7

Answer

11

Question 4

A 45-year-old man on a fat-free, carbohydrate-rich diet for a certain time continues to gain weight and become obese. Which of the following lipoproteins is likely to be elevated in his blood?

Accepted Answer

VLDL

Answer

Chylomicrons

Answer

LDL

Answer

HDL

Question 5

High-density lipoprotein (HDL) levels are increased by which of the following?

Accepted Answer

Exercise

Answer

400 mg Vitamin E daily

Answer

Aspirin

Answer

DHEA

Question 6

Iron-sulfur proteins are components of which of the following metabolic pathways?

Accepted Answer

beta-oxidation

Answer

Citric acid cycle

Answer

ATP synthase

Answer

Respiratory chain

Question 7

Deficiency of which enzyme causes Tay-Sachs disease?

Accepted Answer

Hexosaminidase A

Answer

Alpha-L-iduronidase

Answer

Alpha-galactosidase A

Answer

Acid alpha-glucosidase

Question 8

Which of the following is NOT a component of the multifunctional enzyme Fatty Acid Synthase Complex?

Accepted Answer

Monoamine oxidase

Answer

Acetyl transacylase

Answer

Enoyl reductase

Answer

Malonyl transacylase

Question 9

Which of the following organs cannot utilize fatty acids for energy metabolism, except?

Accepted Answer

Brain

Answer

Liver

Answer

Muscle

Answer

Kidney

Question 10

Saturated acyl enzyme formation causes:

Accepted Answer

Freeing of PAN-SH site

Answer

Freeing of Cyst-SH site

Answer

Both

Answer

None

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?